Halozyme Therapeutics Stock Price (NASDAQ:HALO)

Add to My Stocks
$16.78 $0.18 (1.08%) HALO stock closing price Sep 22, 2017 (Closing)
Prev Close* : $16.60
Market Cap:
$2.36B
Day Low: $16.36
52 Week Low: $8.18
Open: $16.59
Volume: 1178253
Day High: $16.91
52 Week High: $17.55
Dividend:
N/A

Latest Stock Market News

Latest Articles

Halozyme Therapeutics News - From Partners

Halozyme Increases 2017 Financial Guidance   by PRNews on Sep 14, 2017

HALO Stockcharts

View HALO PE ratio, PS ratio stocks charts and compare with peers.
HALO Chart
Note: Compare Halozyme Therapeutics stock price history with the index and industry peers.

Halozyme Therapeutics Valuation

PS ratio (
price to sales ratio
)
16.76

Halozyme Therapeutics Financial Ratios

Asset Turnover
0.47
Receivables Turnover
8.04
Debt to Equity
3.63

HALO Industry Peers

Company Price Change (%)
Blueprint Medicines (BPMC)62.280.18 (0.29%)
Kythera Biopharma (KYTH)74.980 (0%)
Pfizer (PFE)35.960.01 (0.03%)
Abbvie (ABBV)87.480.07 (0.08%)
Eli Lilly (LLY)83.910.58 (0.7%)
Baxalta (BXLT)46.020.18 (0.39%)
Johnson & Johnson (JNJ)131.390.36 (0.27%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
IOVANCE BIOTHPT (IOVA)7.70.7 (10%)
Celldex Therapeutics (CLDX)2.660.2 (8.13%)
MediciNova (MNOV)6.180.3 (5.1%)
Fate Therapeutics (FATE)4.120.18 (4.57%)
Alder BioPharma (ALDR)10.850.4 (3.83%)
Athersys (ATHX)2.550.08 (3.24%)
Vital Therapies (VTL)4.90.15 (3.16%)
Top gainers from Medical-Biomed-Genetics industry
* As of Sep 23, 2017
CompanyPriceChange (%)
Intercept Pharma (ICPT)61.5912.11 (16.43%)
Exelixis (EXEL)24.473.54 (12.64%)
Epizyme (EPZM)16.951.75 (9.36%)
Amicus Therapeutics (FOLD)14.611.17 (7.41%)
Chromadex (CDXC)40.3 (6.98%)
Arbutus Biopharma (ABUS)6.550.45 (6.43%)
AKARI THERAPTC (AKTX)8.180.56 (6.41%)
Top losers from Medical-Biomed-Genetics industry
* As of Sep 23, 2017

Halozyme Therapeutics, Inc. Stock News - Partner Headlines

Halozyme Therapeutics Financial Statements

income statement20162015201420132012
Net Sales or Revenues146.69M135.05M75.33M54.79M42.32M
Net Income-103.02M-32.23M-68.37M-83.47M-53.55M
Total Operating Expense196.69M133.25M115.63M128.97M94.85M
View Halozyme Therapeutics income statement
balance sheet20162015201420132012
Total Assets261.51M181.78M165.97M101.79M134.72M
Total Liabilities293.99M138.79M124.62M121.78M85.87M
Shareholders Equity-32.48M42.99M41.35M-19.99M48.85M
View Halozyme Therapeutics balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) in Assets Liabilities8M-29.49M0.1M22.1M-20.22M
Net Cash from (used by) Operating Activities-50.38M-37.08M-47.51M-49.33M-64.32M
Increase (Decrease) in Prop Plant And Equipment-3.13M-2.36M-1.36M-2.29M-1.41M
View Halozyme Therapeutics cash flow statement

Halozyme Therapeutics Stock Message Board

Halozyme Therapeutics stock lost 1.08 %, and the last close price as of 22 Sep, 2017 is 16.78 for HALO stock. Stock price or share price can be used to find the total market value of a company. Halozyme Therapeutics market cap stands at 2.36B as of 22 Sep, 2017. Halozyme Therapeutics valuation can be guaged using various valuation metrics like the price to earnings ratio.

The stock price movement of a company indicates what investors are willing to pay. For Ex: if investors feel that Halozyme Therapeutics is worth a lot, it will most likely be reflected in an inflated Halozyme Therapeutics stock quote, and vice versa. However, it must be noted that a company's value must not be equated to its share price. The volume of shares traded stood at 1178253 on the last trading day, as is evident from Halozyme Therapeutics stock chart, and HALO stock quote data. To check the historical stock price movement, all time high, and all time low of HALO, view Halozyme Therapeutics stock price history.